Li and colleagues reported that FGFR2 and Src have oncogenic synergies, and targeting Src may serve as a therapeutic strategy for prostate cancer, in which the FGFR2-Src axis is active [26]. The gene discussed is FGFR2; the disease is prostate carcinoma.